骨疏宁片联合阿托伐他汀对2型糖尿病合并绝经后骨质疏松症患者骨密度及骨代谢的影响

目的研究骨疏宁片联合阿托伐他汀对2型糖尿病合并绝经后骨质疏松症患者骨密度及骨代谢的影响。方法 124例2型糖尿病合并骨质疏松症妇女随机分为治疗组和对照组,治疗组进行骨疏宁片联合阿托伐他汀治疗,对照组单纯予以阿托伐他汀治疗。治疗前及治疗后12个月分别检测两组受试者腰椎1~4和左侧股骨颈骨密度、VAS疼痛评分以及骨代谢指标。结果治疗前,各组受试者骨密度、VAS疼痛评分以及骨代谢指标比较无统计学意义(P0.05)。治疗6个月及12个月,两组患者VAS评分不同程度降低,其中以治疗组骨痛的治疗效果要明显优于对照组(P0.05)。治疗12个月两组L1~4椎体、股骨颈的BMD明显升高(P0.05),而治疗组明显高于对照组(P0.05)。治疗12个月,两组血清I型胶原N端前肽(type 1 collagen N terminal peptide,P1NP)的水平明显升高,而I型胶原羧基末端肽(type I collagen carboxy-terminal peptide,CTX)水平明显下降,和对照组比较,治疗组血清P1NP及CTX水平改变更为明显(P0.05)。结论骨疏宁片联合阿托伐他汀可以显著提高2型糖尿病合并骨质疏松症女性骨密度及降低VAS评分,且能改善2型糖尿病合并绝经后骨质疏松症患者骨代谢异常,值得临床推广。

Effect of Gushukening tablets and Atorvastatin on bone mineral density and bone metabolism in type 2 diabetes mellitus patients with postmenopausal osteoporosis

Objective To study the effects of Gushukening tablets and Atorvastatin on bone mineral density and bone metabolism in patients with type 2 diabetes mellitus complicated with postmenopausal osteoporosis. Methods 124 women with type 2 diabetes mellitus complicated with osteoporosis were randomly divided into treatment group and control group. The treatment group was treated with Gushukening tablets and atorvastatin. The control group was treated with atorvastatin alone. Bone mineral density of lumbar spine 1-4 and left femur, VAS pain score and bone metabolic index were measured before and after 12 months of treatment. Results Before treatment, there were no significant differences in bone mineral density, VAS pain score and bone metabolic index between the two groups (P>0.05). At 6 and 12 months of treatment, the VAS score of the two groups decreased in different degrees, and the treatment effect in the treatment group was significantly better than the control group (P<0.05). BMD of the L1-4 vertebrae and the hip increased significantly after 12 months of treatment (P<0.05), and the treatment group had significantly greater increase than the control group (P<0.05). The level of serum P1NP significantly increased and the level of CTX significantly decreased in both groups after 12 months (P>0.05), and the changes in P1NP and CTX levels in the treatment group were significantly greater than those in the control group (P<0.05). Conclusion Gushukening tablets combined with atorvastatin could significantly improve bone mineral density and reduce VAS score in women with type 2 diabetes mellitus combined with osteoporosis, and could improve the abnormal bone metabolism associated with type 2 diabetes combined with osteoporosis, thus is worthy of clinical promotion.